C
ells from the osteoblast lineage play key roles in the regulation of bone development, acquisition of peak bone mass, maintenance and repair of the adult skeleton, and calcium homeostasis (1) . Osteoblast dysfunction leading to bone loss is thought to be a key mechanism in osteoporosis, which affects Ͼ10 million people in the United States and contributes to 1.5 million fractures each year (2) . Bone fractures constitute Ͼ3 million emergency department visits a year in the United States (3) . Although activation of osteoblast G protein-coupled receptors (GPCRs), such as the parathyroid hormone receptor (PTHR1) by recombinant PTH (1-34) (teriparatide), can increase bone mass (4), the exact in vivo roles of the various G protein signaling pathways, and how they interact with other aspects of skeletal biology, have not been clearly elucidated.
GPCRs signal through a select number of pathways, including the G s and G i pathways that influence intracellular cAMP levels (5) . Human genetic diseases involving the G s ␣ subunit (GNAS) suggest that G s signaling can influence bone growth (6) . Inactivation of GNAS in humans leads to multiple endocrinopathies and short stature from rapid growth plate maturation, as seen in Albright's hereditary osteodystrophy (AHO; Online Mendelian Inheritance in Man no. 103580). Mouse models of AHO with chondrocyte-or osteoblast-specific inactivation of GNAS show severe alterations in chondrocyte maturation (7) or cortical bone formation (8) , respectively.
In contrast, abnormal genetic activation of GNAS in humans leads to McCune-Albright syndrome (MAS; Online Mendelian Inheritance in Man no. 174800), which is characterized by alterations in bone and cartilage formation as well as multiple types of endocrine tumors (9) . Mice expressing a constitutively active PTHR1 in osteoblasts show increased trabecular bone volume and decreased cortical bone thickness at 12 weeks of age, with grossly normal femur shape and size (10, 11) . In addition, models using PTH peptide fragments that selectively activate PTHR1-linked G s signaling (12) (13) (14) (15) suggest that G s signaling can increase bone formation. Because a mouse model with constitutively active GNAS in osteoblasts has not been developed, the direct role of activated G s signaling in osteoblasts has not been clearly tested.
We sought to create a system that would permit selective and reversible activation of a single G protein-linked pathway in a tissue-specific manner. Receptors activated solely by a synthetic ligand (RASSLs) provide one method for experimentally manipulating the timing and signaling of G protein pathways (16, 17) . RASSLs are engineered receptors that no longer respond to endogenous hormones but can be activated by synthetic smallmolecule drugs. They have proven useful for studying the roles of activated G protein signaling (18) (19) (20) and basal G protein activity (21, 22) in complex systems, including cardiomyocyte and neurological development and function.
The human 5HT4b serotonin receptor is strongly associated with G s activity and displays high basal signaling that is ideal for constitutively activating the G s pathway. In addition, the large number of pharmacologic agents active on 5HT4 receptors makes this receptor class an ideal substrate for creating RASSLs. Here we use a unique G s -coupled RASSL, Rs1, with constitutive G s signaling activity to examine the temporal and skeletal effects of G s signaling in murine osteoblasts.
Results
To generate Rs1 [ Fig. 1A , and see supporting information (SI) Fig. 5A ] with pharmacological responses similar to those of the murine 5HT4-D100A RASSL (23), we introduced the corresponding D100A mutation and a FLAG tag into the human 5HT4b receptor. In vitro analysis of Rs1 function by transient transfection in HEK293 cells demonstrated that Rs1 had robust basal signaling that increased intracellular cAMP (Fig. 1B) , with no detectable G q -linked basal signaling (SI Fig. 5B ). Because Rs1 does not respond to serotonin (Fig. 1C) , the magnitude of G s -mediated signaling by Rs1 should depend solely on the level of Rs1 expression and not on endogenous serotonin levels, which we cannot control. Rs1 retained agonist-dependent increases in cAMP production in response to several synthetic 5HT4 receptor agonists, including zacopride (Fig. 1D) , demonstrating that the receptor is folded properly, inserted into the plasma membrane, and capable of signaling through the native G s pathway.
Because G s activity is crucial in a variety of tissues, we used the tetracycline transactivator (tTA) system (''TetOff'') (24, 25) to provide temporal control of Rs1 expression (SI Fig. 5C ). To obtain spatial control, TetO-Rs1 transgenic mice were mated with transgenic mice expressing tTA under the control of the osteoblast-specific Col1␣-1 2.3-kb promoter fragment (26) . In the absence of doxycycline, double transgenic progeny [designated ColI(2.3)ϩ/Rs1ϩ] expressed high levels of Rs1 in whole femurs but not in nonskeletal tissues, as assayed by quantitative real-time PCR (qPCR) (Fig. 2A) . These results are consistent with published descriptions of the Col1␣-1 2.3-kb promoter fragment being active in maturing osteoblasts (27, 28) . Little or no Rs1 expression was detected in skeletal tissue from ColI(2.3)ϩ/Rs1ϩ mice maintained on doxycycline or in skeletal tissue from TetO-Rs1 single transgenic mice (SI Fig. 5D ).
Because of the high level of Rs1 transgene expression in ColI(2.3)ϩ/Rs1ϩ mice, we hypothesized that basal Rs1 signaling activity might be sufficient to alter bone mass in vivo. ColI(2.3)ϩ/ Rs1ϩ mice that were maintained off of doxycycline from conception were phenotypically indistinguishable from littermate controls at birth but displayed notable asymmetric enlargement of the skeleton starting at 3 weeks of age. These characteristics became more pronounced and generalized as the mice aged. Although body weights (SI Fig. 6 A and B) for all mice remained similar through 9 weeks of age, double transgenic mice were shorter than their single transgenic and wild-type (WT) littermate controls starting at 6 weeks of age (SI Fig. 6 C and D) .
As determined by dual-energy x-ray absorptiometry (DEXA) scanning, ColI(2.3)ϩ/Rs1ϩ mice displayed an osteosclerotic phenotype with increased bone mineral (Fig. 2B ). At 9 weeks of age, both female (SI Fig. 6E ) and male (SI Fig. 6F ) mice showed dramatic increases (380%) in whole-body areal bone mineral density (BMD) (Fig. 2C) . No significant differences were observed in BMD, weight, or length within the littermate control genotypes [ColI(2.3)ϩ or Rs1ϩ single transgenics and wild types] or between males and females. In addition, three distinct TetO-Rs1 responder transgenic mouse lines gave similar results, confirming that the bony changes were not due to transgene integration effects. ColI(2.3)ϩ/Rs1ϩ mice maintained off of doxycycline continued to show progression of the bone phenotype, requiring euthanasia by 30 weeks of age from complications of spinal stenosis, infection, or failure to thrive. Mice maintained on doxycycline from conception did not develop the bone phenotype.
A more detailed characterization of the bony lesions was obtained by microCT analysis (Fig. 3 A-C) . The bones of ColI(2.3)ϩ/Rs1ϩ newborn mice were normal in structure, location, and size, indicating grossly normal developmental patterning. Whole-skeleton alizarin red staining confirmed normal development of the craniofacial structures, with normal tooth eruption (data not shown). At 3 weeks of age, a moderate increase in femur size and an increase in bone accrual within the skull were evident in ColI(2.3)ϩ/Rs1ϩ mice. High-resolution CT scans of femurs from 3-week-old mice showed a significant replacement of the normal long bone structures within the diaphysis by disorganized trabecular bone ( measurements of femurs from 3-week-old mice showed large increases in femur weight and mid-diaphyseal diameter but not femur length (Fig. 3 F-H) . The fine trabecular structure of the abnormal bone in the ColI(2.3)ϩ/Rs1ϩ mice limited our ability to accurately determine segmented bone density. By 9 weeks of age, significant and generalized bony lesions were noted in all ColI(2.3)ϩ/Rs1ϩ mice (SI Movie 2). No heterotopic bone lesions were identified in any of the mutant mice by dissection or CT scanning. In addition, individual leg tendons and their muscles could be identified by careful dissection, indicating that the bony expansion was not a result of heterotopic ossification. Dramatic increases in total bone volume and trabecular bone volume, with almost complete loss of the cortical shell and marrow space, were seen on histomorphometric analysis of femurs from 9-week-old mice. High-magnification images of both 3-and 9-week-old femurs showed a large number of cells with uniform morphology interdigitated between the trabeculi, with many appearing stacked on and near the rough trabecular surface (Fig. 4 A and B, and see SI Figs. 7 A-C and 8 A and B) . Normal bone marrow structure was disrupted, with loss of the normal bone marrow cavity. Bone marrow elements appeared to be scattered in small islands between the trabeculi (SI Fig. 7 A  and B) . Red blood cell, white blood cell, and platelet counts in the mutant mice were indistinguishable from WT controls through 9 weeks of age. No sites of extramedullary hematopoiesis were identified by histology of the spleen, liver, or kidney. qPCR analysis on 9-week-old WT and ColI(2.3)ϩ/Rs1ϩ bones (Fig. 4 G and H) showed a moderate increase in osteocalcin expression and a dramatic increase in osterix expression, suggesting a relative increase in osteoblast-lineage cells in the ColI(2.3)ϩ/Rs1ϩ bone lesions. Immunohistochemistry with an antibody against the FLAG tag on Rs1 identified a significant number of cells within the ColI(2.3)ϩ/Rs1ϩ bone lesions expressing Rs1 (SI Fig. 7 D and E) . These cells likely represent maturing osteoblasts, based on the known expression patterns of the Col1␣-1 2.3-kb promoter fragment (27, 28) and on the presence of abundant osteocalcin in the bone lesions (SI Fig. 7  F and G) . Osterix expression was detected by immunohistochemistry in WT animals (SI Fig. 7 J and K) only in the trabecular bone at the epiphysis. In contrast, osterix was easily detected throughout the ColI(2.3)ϩ/Rs1ϩ bone lesions (SI Fig. 7 L and  M) . These immunohistochemistry results confirm that many of the uniform cells in the ColI(2.3)ϩ/Rs1ϩ bone lesions are in the osteoblast lineage. The requirement for different fixation methods precluded us from colocalization of Rs1 with osterix or osteocalcin on these samples.
We used dual fluorochrome labeling to examine the bone formation rate and pattern in 3-week-old (SI Fig. 8 C and D) and 9-week-old (Fig. 4 C and D) ColI(2.3)ϩ/Rs1ϩ mice. The mutant mice showed disordered bone formation, indicated by punctate labeling seen at high magnification, preventing accurate measurement of bone formation rates. Low-magnification images showed several regions of relatively discrete xylenol orange or calcein labeling interspersed with regions labeled with both fluorochromes, suggesting localized regions of high bone turnover. Rapid bone turnover was also suggested by the large number of tartrate-resistant acid phosphatase (TRAP)-positive regions adjacent to the trabeculi within the lesions (Fig. 4 E and F, and see SI Fig. 8 E and F) , indicating an increase in osteoclast number. Basic serum parameters were similar in all genotypes in 3-week-old (SI Table 2 ) and 9-week-old (SI Table 3 ) mice. In contrast, markers of bone turnover were increased in the affected mice at both ages (Fig. 4 I-K) . These results, along with the nodular pattern seen on fluorochrome labeling and on cross-sectional CT analysis, suggest that the bony lesions contain regions of extremely high rates of bone formation and turnover consistent with rapid remodeling activity.
We used the tTA system to determine whether expression of Rs1 during the period of rapid bone growth in the first several weeks of life is required for the full effect of Rs1 on bone formation. Rs1 expression was suppressed up to weaning (3 weeks of age) by administration of doxycycline to mothers during pregnancy and lactation. After weaning, pups were maintained on doxycycline-containing food for an additional week and then switched to a doxycycline-free diet to allow Rs1 expression. Longitudinal assessment of these mice did not show a detectable bone phenotype by DEXA BMD, weight, or length measurements through 30 weeks of age (SI Fig. 9 ). Our results suggest that the dramatic effect of Rs1 on bone accrual requires expression of Rs1 during the first 4-6 weeks of murine life.
Discussion
Our studies demonstrate that osteoblast expression of Rs1, an engineered G s -coupled RASSL with constitutive G s activity, induces a dramatic anabolic bone effect that is significantly different from previous models (10) (11) (12) (13) (14) (15) . The ColI(2.3)ϩ/Rs1ϩ mice display several unique and unexpected characteristics, including a crucial temporal requirement for Rs1 expression, an unusually large amount of bone mineral accrual, and effects on bone macroarchitecture. Our results add to prior studies (10) (11) (12) (13) (14) (15) that support the anabolic role of G s signaling in osteoblasts by using a model system that controls G s activation without potential confounding effects from endogenous ligands or nonskeletal PTHR1 activation. In addition, Rs1 basal signaling activity appears to be selective for the G s pathway, with little or no activation of the G q pathway. Thus, the lesser effect of constitutively active PTHR1 signaling on bone mass (10) may be attributable to PTHR1-induced activation of additional G protein signaling pathways, including G i and G q , that could counteract the anabolic effects of G s activation. Recent studies lend support to this notion, because osteoblast expression of a constitutively active G q ␣ (29) or a constitutively active G icoupled GPCR (26, 30) leads to decreased trabecular bone. Mice expressing the constitutively active PTHR1 also show expansion of trabecular bone, with delay of bone marrow cavity formation (31); however, the ColI(2.3)ϩ/Rs1ϩ mice appear to have a more severe phenotype and do not appear to reform a true bone marrow space as they age.
The dramatic loss of cortical bone in the ColI(2.3)ϩ/Rs1ϩ lesions is reminiscent of that found in primary hyperparathyroidism, in which continuous PTHR1 receptor activation by PTH leads to a decrease in cortical bone mass. Patients with primary hyperparathyroidism show largely unaffected trabecular bone structures (32, 33) , which contrasts sharply with the massive increases in trabecular bone seen in the ColI(2.3)ϩ/Rs1ϩ mice. We speculate that the enhanced expansion of trabecular bone in the ColI(2.3)ϩ/Rs1ϩ mice may be a result of chronic G s activation during the prepubertal growth phase and that PTHR1-induced G i and G q signaling may be modulated in normal prepubertal growth to allow rapid expansion of the growing skeleton. Furthermore, intermittent administration of recombinant PTH to adult patients leads to an increase in both cortical bone mass and bone strength (34, 35) . The differences in response to intermittent vs. chronic PTHR1 activation indicate that basal vs. ligand-induced G s activity may regulate the balance between cortical and trabecular bone formation.
Our data show that osteoblast-lineage cells in prepubertal mice have an enormous bone-forming capacity. Many clinical conditions affecting bone show age-dependence. Several types of primary skeletal tumors, including osteosarcoma and Ewing's sarcoma, have a higher prevalence in children and adolescents than in adults (36, 37) . In addition, older patients (38-41) and older animals (42-44) recover more slowly after certain types of fracture. Recent animal studies in young rats (45) , and clinical studies in young children (46) , suggest that exercise during childhood can lead to an increase in bone mass that persists with age. The ColI(2. predominantly pediatric disease caused by the expression of a constitutively active form of G s ␣ (47). This sensitivity of early postnatal osteoblasts to G s activation may provide a cellular explanation for these age-related differences in bone growth and healing. Stem cell and osteoblast models could be developed to determine the cellular basis of the ColI(2.3)ϩ/Rs1ϩ phenotype and to further investigate the roles of specific signaling pathways as downstream mediators of Rs1 activity. Direct, controlled regulation of the yet-to-be-identified anabolic target may also be useful for improving fracture healing or surgical repair, as well as for developing potential treatments for skeletal diseases such as fibrous dysplasia (9), osteoblastomas, osteoid sarcomas (48, 49) , and osteoblastic bone metastases (50) . Our RASSL system will also permit examination of the contributions of both basal G s signaling activity and ligand-mediated receptor activation. Such studies have exciting implications for revealing new mechanisms for the control of bone formation.
Materials and Methods
Constructs. The WT human 5HT4b receptor cDNA was obtained from W. Kroeze and B. Roth (University of North Carolina, Chapel Hill, NC). The human 5HT4b cDNA coding region was amplified by PCR cloning (primers are listed in SI Table 1 A) to introduce flanking NotI cloning sites. The 5HT4b PCR fragment was used to replace the entire 5HT2c receptor coding region via the NotI sites of the pUNIV-5HT2c-INI plasmid (also kindly provided by W. Kroeze and B. Roth) in frame with the existing signal peptide and the FLAG epitope (DKY-DDDDA). The 5HT4-D100A mutation was introduced by using the QuikChange site-directed mutagenesis kit (Stratagene) and the sense primer (SI Table 1B) to generate the Rs1 receptor in the plasmid pUNIV-SIG-5HTR4D100A (Addgene plasmid database no. 16312). All constructs were verified by sequencing. The pUNIV-SIG-5HTR4D100A plasmid was used directly for expression and signaling analysis in HEK293 cells.
cAMP Production and Calcium Mobilization Assays. These assays were performed as described in SI Materials and Methods, using the Hi-Range HTRF kit (CisBio) and FLIPR Calcium4 flurometric plate reader assay (Molecular Devices).
Generation of Mice.
All transgenic mouse studies were approved by, and performed in accordance with, the Institutional Animal Care and Use Committee and the Laboratory Animal Research Center at the University of California, San Francisco.
TetO-Rs1 Construct and Transgenic Mouse. To regulate expression of Rs1 with tetracycline or doxycycline, the Rs1 cDNA construct was cloned into the pUHG10.3 vector (51) containing the TetO promoter, ␤-globin intron, and pA sites (pUHG10.3 TetO-Rs1; Addgene plasmid no. 16313). A 3-kb XhoI/SapI fragment was isolated by restriction digestion and used to generate the TetO-Rs1 transgenic mice by pronuclear injection into FVBN oocytes (Gladstone Transgenic Core). Chimeric mice were backcrossed and maintained on a FVBN background. Seven chimeric mice were identified, and three lines (designated B, C, and G) demonstrated germ-line transmission by PCR genotyping (SI Table 1 (26) , to generate the experimental double transgenic genotype and the three control genotypes (see SI Fig. 5A for mating strategy) . Transgene expression was suppressed with doxycycline-impregnated mouse chow (DoxDiet 200 mg/kg; BioServ). Transgene expression was activated by switching the mice to regular mouse chow without doxycycline at 4 weeks of age (LabDiet 5053; PMI Nutrition). Full transgene expression was expected to occur within 2 weeks after doxycycline withdrawal, based on prior data (20) . qPCR from whole femurs of 6-week-old adult mice showed that Rs1 expression was induced Ϸ4-to 80-fold above that of age-matched ColI(2.3)ϩ/Rs1ϩ mice that were chronically maintained on doxycycline (SI Fig. 5D ). qPCR and serum analyses were carried out as described in SI Materials and Methods.
Bone Imaging. Mice identified for bone densitometry (DEXA) scans were anesthetized with inhaled isofluorane (1.5-2% in oxygen) and scanned at predetermined time points using a Lunar PIXImus2 (GE Lunar). Whole-mouse and femur CT scans were performed on euthanized animals with a vivaCT40 microCT scanning system (Scanco), as described in SI Materials and Methods.
Histology and Immunohistochemistry. Mice identified for histomorphometry were injected with calcein (Sigma-Aldrich) at day Ϫ7 and with xylenol orange (Sigma-Aldrich) at day Ϫ2 before harvesting. Isolated bone samples were processed as described in SI Materials and Methods.
